These findings underscore LSD1’s dual regulatory axes—LSD1-H3K4me2-CD47/PD-L1 and LSD1-p53-miR-34a-CD47/PD-L1—as key mechanisms driving immune evasion in cervical cancer, positioning LSD1 inhibition as a promising strategy to augment immunotherapy [185]. The gene discussed is CD47; the disease is cervical cancer.